ES2167733T3 - Inhibidores de metaloproteinasa matricial de bifenilsulfonamida. - Google Patents

Inhibidores de metaloproteinasa matricial de bifenilsulfonamida.

Info

Publication number
ES2167733T3
ES2167733T3 ES97918788T ES97918788T ES2167733T3 ES 2167733 T3 ES2167733 T3 ES 2167733T3 ES 97918788 T ES97918788 T ES 97918788T ES 97918788 T ES97918788 T ES 97918788T ES 2167733 T3 ES2167733 T3 ES 2167733T3
Authority
ES
Spain
Prior art keywords
bifenylsulfonamide
alkyl
matrix metaloproteinase
metaloproteinase inhibitors
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97918788T
Other languages
English (en)
Spanish (es)
Inventor
Patrick Michael O'brien
Drago Robert Sliskovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of ES2167733T3 publication Critical patent/ES2167733T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/42—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
ES97918788T 1996-05-17 1997-04-24 Inhibidores de metaloproteinasa matricial de bifenilsulfonamida. Expired - Lifetime ES2167733T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1746096P 1996-05-17 1996-05-17

Publications (1)

Publication Number Publication Date
ES2167733T3 true ES2167733T3 (es) 2002-05-16

Family

ID=21782716

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97918788T Expired - Lifetime ES2167733T3 (es) 1996-05-17 1997-04-24 Inhibidores de metaloproteinasa matricial de bifenilsulfonamida.

Country Status (22)

Country Link
EP (1) EP0901466B1 (enExample)
JP (1) JP2000511175A (enExample)
KR (1) KR20000011095A (enExample)
CN (1) CN1077885C (enExample)
AT (1) ATE207891T1 (enExample)
BG (1) BG63940B1 (enExample)
BR (1) BR9710841A (enExample)
CA (1) CA2253342A1 (enExample)
CZ (1) CZ294063B6 (enExample)
DE (1) DE69707865T2 (enExample)
DK (1) DK0901466T3 (enExample)
EA (1) EA001561B1 (enExample)
EE (1) EE03965B1 (enExample)
ES (1) ES2167733T3 (enExample)
IL (1) IL126832A0 (enExample)
NO (1) NO312510B1 (enExample)
NZ (1) NZ332711A (enExample)
PL (1) PL186416B1 (enExample)
PT (1) PT901466E (enExample)
SK (1) SK282863B6 (enExample)
WO (1) WO1997044315A1 (enExample)
ZA (1) ZA974223B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0766665B1 (en) * 1994-06-22 1999-07-28 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US6124333A (en) * 1995-06-22 2000-09-26 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
WO1998025597A2 (en) * 1996-12-09 1998-06-18 Warner-Lambert Company Method for treating and preventing heart failure and ventricular dilatation
JP2001507342A (ja) 1996-12-17 2001-06-05 ワーナー−ランバート・コンパニー 神経疾患の治療および創傷治癒を促進するためのマトリックスメタロプロテイナーゼ阻害剤の使用
SI0946166T1 (en) * 1996-12-17 2004-06-30 Warner-Lambert Company Llc Use of matrix metalloproteinase inhibitors for promoting wound healing
GB9706255D0 (en) 1997-03-26 1997-05-14 Smithkline Beecham Plc Novel compounds
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
PL338235A1 (en) 1997-07-22 2000-10-09 Shionogi & Co Preparation for treating or preventing glomerulopathic states
AU751701B2 (en) * 1997-12-23 2002-08-22 Warner-Lambert Company Ace inhibitor-MMP inhibitor combinations
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
IL137465A0 (en) * 1998-02-04 2001-07-24 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
NZ505994A (en) * 1998-03-17 2003-10-31 Warner Lambert Co Statin-matrix metalloproteinase inhibitor combinations useful fro treating vascular diseases
EP0967201A1 (en) * 1998-05-20 1999-12-29 Roche Diagnostics GmbH Pharmaceutical agents containing sulfonamids as matrix metalloproteinase inhibitors
DE59903329D1 (en) * 1998-07-16 2002-12-12 Aventis Pharma Gmbh Phosphin- und phosphonsäurederivate als arzneimittel
CA2335062A1 (en) * 1998-07-21 2000-02-03 Thomas Michael Andrew Bocan Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
DE19851184A1 (de) * 1998-11-06 2000-05-11 Aventis Pharma Gmbh N-Arylsulfonyl-aminosäure-omega-amide
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
PL351374A1 (en) * 1999-04-19 2003-04-07 Shionogi & Co Sulfonamide derivatives having oxadiazole rings
GB9918684D0 (en) 1999-08-09 1999-10-13 Novartis Ag Organic compounds
JP3910446B2 (ja) 1999-11-26 2007-04-25 塩野義製薬株式会社 Ｎｐｙｙ５拮抗剤
CA2423885A1 (en) * 2000-09-29 2003-03-27 Shionogi & Co., Ltd. Thiazole and oxazole derivatives
GB0103303D0 (en) 2001-02-09 2001-03-28 Novartis Ag Organic compounds
MXPA01013326A (es) 2001-02-14 2002-08-26 Warner Lambert Co Bifenil sulfonamidas utiles como inhibisdores de metaloproteinasa de matriz.
JP4219810B2 (ja) * 2001-10-26 2009-02-04 塩野義製薬株式会社 Ｍｍｐ阻害作用を有するスルホンアミド誘導体
GB0314488D0 (en) * 2003-06-20 2003-07-23 Glaxo Group Ltd Therapeutically useful compounds
JP2007525406A (ja) * 2003-12-04 2007-09-06 ワイス ビアリールスルホンアミドおよびその使用方法
US8129406B2 (en) * 2004-03-22 2012-03-06 Southern Research Institute Nonpeptide inhibitors of matrix metalloproteinases
CN101279956B (zh) * 2008-04-25 2011-06-15 南昌大学 一种基质金属蛋白酶抑制剂及合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506242A (en) * 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
EP0766665B1 (en) * 1994-06-22 1999-07-28 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors

Also Published As

Publication number Publication date
CN1077885C (zh) 2002-01-16
ZA974223B (en) 1997-12-10
BR9710841A (pt) 1999-08-17
PL329929A1 (en) 1999-04-26
JP2000511175A (ja) 2000-08-29
WO1997044315A1 (en) 1997-11-27
DK0901466T3 (da) 2002-02-18
SK282863B6 (sk) 2002-12-03
DE69707865T2 (de) 2002-05-02
PL186416B1 (pl) 2004-01-30
CA2253342A1 (en) 1997-11-27
EP0901466B1 (en) 2001-10-31
BG102918A (en) 1999-09-30
NZ332711A (en) 2000-06-23
NO312510B1 (no) 2002-05-21
KR20000011095A (ko) 2000-02-25
BG63940B1 (bg) 2003-07-31
PT901466E (pt) 2002-04-29
ATE207891T1 (de) 2001-11-15
IL126832A0 (en) 1999-08-17
CN1219166A (zh) 1999-06-09
AU2680397A (en) 1997-12-09
SK157798A3 (en) 1999-04-13
NO985326L (no) 1999-01-14
DE69707865D1 (de) 2001-12-06
EA199800988A1 (ru) 1999-04-29
AU713286B2 (en) 1999-11-25
HK1019585A1 (en) 2000-02-18
EE9800397A (et) 1999-06-15
CZ366898A3 (cs) 1999-02-17
CZ294063B6 (cs) 2004-09-15
EA001561B1 (ru) 2001-04-23
EE03965B1 (et) 2003-02-17
NO985326D0 (no) 1998-11-16
EP0901466A1 (en) 1999-03-17

Similar Documents

Publication Publication Date Title
ES2167733T3 (es) Inhibidores de metaloproteinasa matricial de bifenilsulfonamida.
AU6894800A (en) Caspase inhibitors and uses thereof
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
WO2003024448A3 (en) Inhibitors of histone deacetylase
NO996269L (no) Kinolin-indol antimikrobielle midler, samt anvendelse og blandinger derav
ATE289590T1 (de) Beta-sulfonyl-hydroxamsäuren als matrix- metalloproteinaseinhibitoren
NZ332762A (en) Isobutylgaba and its derivatives for the treatment of pain
PL343495A1 (en) Heterocyclically substituted amides used as calpain inhibitors
BR9805544A (pt) Uso de um composto.
DK0840732T3 (da) Substituerede benzolactamforbindelser som substans P-antagonister
AU2001248701A1 (en) Inhibitors of histone deacetylase
DE69811111D1 (de) Hydroxamsäure- und carbonsäurederivate mit mmp und tnf hemmender wirkung
DK0946166T3 (da) Anvendelse af matrixmetalloproteinaseinhibitorer til fremme af sårheling
NZ333550A (en) Matrix metalloproteinase inhibitors for inhibiting the release of TNF
CA2266759A1 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
AU1314300A (en) Methods and compositions for inhibiting polymerization of ethylenically unsaturated hydrocarbons
AU2001255646A1 (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoindane derivatives
CO4900041A1 (es) Inhibidores de metaloproteinasa de matriz de acido butirico enzimas metaloproteinasa de matriz y metodo de tratamiento con los mismos
WO2004048368A3 (en) Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors
ES2173634T3 (es) Compuestos heterociclicos que presentan actividad inhibidora de mmp y tnf.
PT971714E (pt) Metodo utilizando inibidores ciclooxigenase-2 no tratamento e prevencao da demencia
NO20075410L (no) Vetrinaerbruk av et pleuromutilinderivat